Navigation Links
FDA Puts Partial Hold on Avandia Safety Study
Date:7/21/2010

WEDNESDAY, July 21 (HealthDay News) -- No new patients will be permitted to enroll in a safety study of the controversial diabetes drug Avandia until further notice, the U.S. Food and Drug Administration announced Wednesday.

But under the partial clinical trial hold, those patients already enrolled in the TIDE (Thiazolidinedione Intervention With Vitamin D Evaluation) trial will be allowed to continue to participate, the agency said in a news release.

An FDA advisory panel last week ruled that Avandia (rosiglitazone) does boost users' heart risks, but it also decided that the drug should stay on the market because there's no definitive evidence of an increased risk.

The FDA said Wednesday that it is evaluating available data on Avandia's safety and the discussions from last week's advisory panel meeting. When the review is complete, the agency will inform the public about the findings and what they mean for the drug's status and the TIDE trial.

GlaxoSmithKline, which makes Avandia, was told by the FDA to update researchers, institutional review boards and ethics committees involved in the TIDE trial about new safety information presented at the FDA advisory panel meeting. That information can be used to update informed consent information for people already enrolled in the TIDE trial, the FDA said.

GSK agreed to conduct the TIDE trial in 2007 after concerns about the safety of Avandia first became public. The goal of the trial is to determine whether Avandia poses greater heart risks than a competing drug called Actos.

In a news release, the drug company confirmed that it will suspend enrollment of new patients in the TIDE trial and send a summary of recent safety data and a summary of the FDA advisory panel meeting to all TIDE researchers and institutional review boards.

"This pause in enrollment will give clinical trial investigators and patients time to learn about the data presented to the FDA Advisory Committee and the Committee's recommendations," Dr. Ellen Strahlman, GSK's chief medical officer, said in the news release.

"Patients with questions about the use of Avandia should talk with their physicians," she added.

More information

The U.S. National Library of Medicine has more about rosiglitazone.

-- Robert Preidt

SOURCES: U.S. Food and Drug Administration and GlaxoSmithKline, news releases, July 21, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
2. Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures
3. Study shows partial lung removal favorable over full removal as treatment for lung cancer
4. Hip surgery success partially predicted by number of other existing conditions
5. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
6. Remove Diabetes Drug Avandia From Market: FDA Reports
7. Remove Diabetes Drug Avandia From Market: FDA Documents
8. FDA Says It Hasnt Decided Whether to Pull Diabetes Drug Avandia Off the Market
9. FDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the Market
10. Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
11. Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Puts Partial Hold on Avandia Safety Study
(Date:3/30/2017)... ... 2017 , ... This morning, more than 275 medical doctors, ... for an independent Vaccine Safety Commission. Five of the signers of the letter, ... a press conference at 9:00 AM Friday, March 31 at the National ...
(Date:3/29/2017)... Georgia (PRWEB) , ... March 29, 2017 , ... Full ... Therilus, founder of Pet Protect Law that assists dog owners in creating ... assist new owners in taking the natural next step to protect their new companion. ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of the ... Forecast" report to their offering. ... Proton Therapy Market in Italy will ... There are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton ...
(Date:3/29/2017)... 2017  The Global Health Innovative Technology Fund ... to battle infectious diseases around the globe, today ... could help deliver a range of new innovative ... This latest round of targeted support ... testing a pediatric formulation of a drug considered ...
Breaking Medicine Technology: